Accrual-Monitoring Practices for Various Disease Trials among AACI Member Cancer Centers.

Authors

• Zachary T Elliott
• Zachary Goldberg
• Ramez Philips
• Jennifer M Johnson
• Margaret T Kasner
• William K Kelly
• Sarah Osipowicz
• Rachael Dampman
• Joseph M Curry

Publication/Presentation Date

8-31-2022

Abstract

Progress in the management of rare diseases, including rare cancers, is dependent upon clinical trials; however, as many as 32% of rare-disease trials go uncompleted or unpublished due to insufficient accrual. Monitoring practices may differ between institutions. We sought to survey the regulatory standards for various trial types among major U.S. cancer centers. A 10-question survey was designed using Qualtrics assessment software. The survey was sent via email to an internal server of member institutions of the Association of American Cancer Institutes (AACI). Of 103 AACI centers, 31% completed the survey (

Volume

12

Issue

5

First Page

692

Last Page

700

ISSN

2039-7275

Published In/Presented At

Elliott, Z. T., Goldberg, Z., Philips, R., Johnson, J. M., Kasner, M. T., Kelly, W. K., Osipowicz, S., Dampman, R., & Curry, J. M. (2022). Accrual-Monitoring Practices for Various Disease Trials among AACI Member Cancer Centers. Clinics and practice, 12(5), 692–700. https://doi.org/10.3390/clinpract12050072

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

36136866

Department(s)

Administration and Leadership

Document Type

Article